Possible effect of medroxyprogesterone acetate (MPA) in lymphoid blast crisis of chronic myelogenous leukemia.

Abstract

A patient with a lymphoid blast crisis of a chronic myelogenous leukemia (CML) was treated with vindesine, vincristine and prednisone. Blasts disappeared from the peripheral blood but persisted at a level of 60% in the bone marrow. After 5 weeks of continuous therapy, the patient became thrombopenic, and 2 weeks later blasts rose to 31%. After 7 weeks, 1 g MPA was given daily p.o. and weekly vincristine treatment was resumed. Blasts disappeared again from the peripheral blood, thrombocytes rose to a maximum of 274 g/l, and a remission with less than 5% blasts was demonstrated in the bone marrow. In another relapse after withdrawal of MPA, estrogen and progesterone receptors (PR) were found in the leukemic cells. Thus, a remission was seen during treatment with vincristine, prednisone, and MPA after a deterioration with vincristine and prednisone alone in a PR-positive leukemia, and an effect of MPA in this lymphoid blast crisis of a CML has to be discussed.

• Authors: M Fink
• Journal: Annals of hematology (Ann Hematol) Vol. 68 Issue 2 Pg. 89-90 (Feb 1994) ISSN: 0939-5555 [Print] Germany
• PMID: 8148420 (Publication Type: Case Reports, Journal Article)

Chemical References

• Vincristine
• Medroxyprogesterone Acetate
• Prednisone

Topics

• Blast Crisis
• Blood Cells (pathology)
• Bone Marrow (pathology)
• Drug Therapy, Combination
• Female
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, pathology)
• Medroxyprogesterone Acetate (therapeutic use)
• Middle Aged
• Prednisone (therapeutic use)
• Vincristine (therapeutic use)